| 27 Mar 2026 | 08:00:00 | Readmission - Roquefort Therapeutics Plc |
| 26 Mar 2026 | 13:00:01 | Investor Presentation |
| 26 Mar 2026 | 12:08:49 | Result of General Meeting |
| 25 Mar 2026 | 07:00:09 | Lyramid SPA & MK Cell License Update |
| 2 Mar 2026 | 08:00:00 | Schedule One - Roquefort Therapeutics PLC |
| 20 May 2025 | 2024 Annual Report | |
| 1 May 2024 | 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS | |
| 26 Apr 2024 | Annual Report & Financial Statements - 31 Dec 2023 |
Roquefort Therapeutics is a firm that aims to invest in medical biotechnology startups in their early stages to generate maximum returns for both the startups and our investors.
| 27 Mar 2026 | 08:00:00 | Readmission - Roquefort Therapeutics Plc |
| 26 Mar 2026 | 13:00:01 | Investor Presentation |
| 26 Mar 2026 | 12:08:49 | Result of General Meeting |
| 25 Mar 2026 | 07:00:09 | Lyramid SPA & MK Cell License Update |
| 2 Mar 2026 | 08:00:00 | Schedule One - Roquefort Therapeutics PLC |
| 20 May 2025 | 2024 Annual Report | |
| 1 May 2024 | 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS | |
| 26 Apr 2024 | Annual Report & Financial Statements - 31 Dec 2023 |
Roquefort Therapeutics is a firm that aims to invest in medical biotechnology startups in their early stages to generate maximum returns for both the startups and our investors.